Lista de obras -

3D Mass Spectrometry Imaging Reveals a Very Heterogeneous Drug Distribution in Tumors

artículo científico publicado en 2016

A Nanostructured Matrices Assessment to Study Drug Distribution in Solid Tumor Tissues by Mass Spectrometry Imaging.

artículo científico publicado en 2017

A biodistribution study of PEGylated PCL-based nanoparticles in C57BL/6 mice bearing B16/F10 melanoma.

artículo científico publicado en 2014

Antiangiogenic activity of trabectedin in myxoid liposarcoma: Involvement of host TIMP-1 and TIMP-2 and tumor thrombospondin-1

artículo científico publicado en 2014

Antitumor and anti-inflammatory effects of trabectedin on human myxoid liposarcoma cells.

artículo científico publicado en 2010

Application of 3D Mass Spectrometry Imaging to TKIs

artículo científico publicado en 2017

Assessing the anti-tumour properties of Iraqi propolis in vitro and in vivo

artículo científico publicado en 2012

Base excision repair-mediated resistance to cisplatin in KRAS(G12C) mutant NSCLC cells.

artículo científico publicado en 2015

Bevacizumab-Induced Inhibition of Angiogenesis Promotes a More Homogeneous Intratumoral Distribution of Paclitaxel, Improving the Antitumor Response.

artículo científico publicado en 2015

Bioreducible Hydrophobin-Stabilized Supraparticles for Selective Intracellular Release.

artículo científico publicado en 2017

Chemical characterization of Iraqi propolis samples and assessing their antioxidant potentials

article

Clinical pharmacokinetics of the new oral camptothecin gimatecan: the inter-patient variability is related to alpha1-acid glycoprotein plasma levels.

artículo científico publicado en 2009

Combination of PPARγ Agonist Pioglitazone and Trabectedin Induce Adipocyte Differentiation to Overcome Trabectedin Resistance in Myxoid Liposarcomas

artículo científico publicado en 2019

Comparison of in vitro and in vivo biological effects of trabectedin, lurbinectedin (PM01183) and Zalypsis® (PM00104).

artículo científico publicado en 2013

Determination of total and lactone form of a new camptothecin derivative gimatecan (ST1481) and its metabolite ST1698 in human plasma by high-performance liquid chromatography with fluorimetric detection.

artículo científico publicado en 2009

Differences between in vivo and in vitro sensitivity to imatinib of Bcr/Abl+ cells obtained from leukemic patients.

artículo científico publicado en 2002

Establishment and characterisation of a new patient-derived model of myxoid liposarcoma with acquired resistance to trabectedin

artículo científico publicado en 2019

Expression of thrombospondin-1 by tumor cells in patient-derived ovarian carcinoma xenografts.

artículo científico publicado en 2015

G-quadruplex ligand RHPS4 potentiates the antitumor activity of camptothecins in preclinical models of solid tumors.

artículo científico publicado en 2008

HMGA1/E2F1 axis and NFkB pathways regulate LPS progression and trabectedin resistance

artículo científico publicado en 2018

HPLC-MS/MS method to measure trabectedin in tumors: preliminary PK study in a mesothelioma xenograft model

artículo científico publicado en 2015

Heterogeneity of paclitaxel distribution in different tumor models assessed by MALDI mass spectrometry imaging

artículo científico publicado en 2016

High-performance liquid chromatographic assay for the determination of Aloe Emodin in mouse plasma.

artículo científico publicado en 2003

High-performance liquid chromatographic assay for the determination of the novel C-Seco-taxane derivative (IDN 5390) in mouse plasma

artículo científico publicado en 2002

High-performance liquid chromatographic assay for the determination of the novel taxane derivative IDN5109 in mouse plasma

artículo científico publicado en 1999

Human malignant mesothelioma is recapitulated in immunocompetent BALB/c mice injected with murine AB cells.

artículo científico publicado en 2016

IDN 5390: an oral taxane candidate for protracted treatment schedules

artículo científico publicado en 2003

Inactivation of DNA repair triggers neoantigen generation and impairs tumour growth.

artículo científico publicado en 2017

Increased sensitivity to platinum drugs of cancer cells with acquired resistance to trabectedin

artículo científico publicado en 2015

Longitudinal tracking of triple labeled umbilical cord derived mesenchymal stromal cells in a mouse model of Amyotrophic Lateral Sclerosis

artículo científico publicado en 2015

Lurbinectedin reduces tumour-associated macrophages and the inflammatory tumour microenvironment in preclinical models

artículo científico publicado en 2017

Mode of action of trabectedin in myxoid liposarcomas.

artículo científico publicado en 2013

Novel models of myxoid liposarcoma xenografts mimicking the biological and pharmacologic features of human tumors.

artículo científico publicado en 2010

OTX015 (MK-8628), a novel BET inhibitor, exhibits antitumor activity in non-small cell and small cell lung cancer models harboring different oncogenic mutations

artículo científico publicado en 2016

PEGylated Nanoparticles Obtained through Emulsion Polymerization as Paclitaxel Carriers

artículo científico publicado en 2015

Past-in-the-Future. Peak detection improves targeted mass spectrometry imaging

scientific article published on 28 June 2018

Patient-derived solitary fibrous tumour xenografts predict high sensitivity to doxorubicin/dacarbazine combination confirmed in the clinic and highlight the potential effectiveness of trabectedin or eribulin against this tumour.

artículo científico publicado en 2017

Pharmacokinetics and antineoplastic activity of galectin-1-targeting OTX008 in combination with sunitinib.

artículo científico publicado en 2013

Pharmacokinetics and metabolism in mice of IDN 5390 (13-(N-Boc-3-i-butylisoserinoyl)-C-7,8-seco-10-deacetylbaccatin III), a new oral c-seco-taxane derivative with antiangiogenic property effective on paclitaxel-resistant tumors.

artículo científico publicado en 2006

Promising in vivo efficacy of the BET bromodomain inhibitor OTX015/MK-8628 in malignant pleural mesothelioma xenografts

artículo científico publicado en 2016

Readily prepared biodegradable nanoparticles to formulate poorly water soluble drugs improving their pharmacological properties: The example of trabectedin

artículo científico publicado en 2018

Reduced expression of the ROCK inhibitor Rnd3 is associated with increased invasiveness and metastatic potential in mesenchymal tumor cells

artículo científico publicado en 2010

Role of Macrophage Targeting in the Antitumor Activity of Trabectedin

artículo científico publicado en 2013

Self-Assembling PCL-Based Nanoparticles as PTX Solubility Enhancer Excipients

artículo científico publicado en 2018

Sequence dependent antitumour efficacy of the vascular disrupting agent ZD6126 in combination with paclitaxel.

artículo científico publicado en 2007

Snail levels control the migration mechanism of mesenchymal tumor cells.

artículo científico publicado en 2016

The bromodomain inhibitor OTX015 (MK-8628) exerts anti-tumor activity in triple-negative breast cancer models as single agent and in combination with everolimus

artículo científico publicado en 2016

The effects of vandetanib on paclitaxel tumor distribution and antitumor activity in a xenograft model of human ovarian carcinoma

artículo científico publicado en 2009

The impairment of the High Mobility Group A (HMGA) protein function contributes to the anticancer activity of trabectedin

article

The isothiocyanate produced from glucomoringin inhibits NF-kB and reduces myeloma growth in nude mice in vivo.

artículo científico publicado en 2009

The neuroprotective effect of erythropoietin in docetaxel-induced peripheral neuropathy causes no reduction of antitumor activity in 13762 adenocarcinoma-bearing rats

artículo científico publicado en 2009

Trabectedin efficacy in Ewing sarcoma is greatly increased by combination with anti-IGF signaling agents.

artículo científico publicado en 2015

Tumor-associated macrophages and anti-tumor therapies: complex links

artículo científico publicado en 2016

Wee1 inhibitor MK1775 sensitizes KRAS mutated NSCLC cells to sorafenib.

artículo científico publicado en 2018

Lista de obras de

3D Mass Spectrometry Imaging Reveals a Very Heterogeneous Drug Distribution in Tumors

A Nanostructured Matrices Assessment to Study Drug Distribution in Solid Tumor Tissues by Mass Spectrometry Imaging.

A biodistribution study of PEGylated PCL-based nanoparticles in C57BL/6 mice bearing B16/F10 melanoma.

Antiangiogenic activity of trabectedin in myxoid liposarcoma: Involvement of host TIMP-1 and TIMP-2 and tumor thrombospondin-1

Antitumor and anti-inflammatory effects of trabectedin on human myxoid liposarcoma cells.

Application of 3D Mass Spectrometry Imaging to TKIs

Assessing the anti-tumour properties of Iraqi propolis in vitro and in vivo

Base excision repair-mediated resistance to cisplatin in KRAS(G12C) mutant NSCLC cells.

Bevacizumab-Induced Inhibition of Angiogenesis Promotes a More Homogeneous Intratumoral Distribution of Paclitaxel, Improving the Antitumor Response.

Bioreducible Hydrophobin-Stabilized Supraparticles for Selective Intracellular Release.

Chemical characterization of Iraqi propolis samples and assessing their antioxidant potentials

Clinical pharmacokinetics of the new oral camptothecin gimatecan: the inter-patient variability is related to alpha1-acid glycoprotein plasma levels.

Combination of PPARγ Agonist Pioglitazone and Trabectedin Induce Adipocyte Differentiation to Overcome Trabectedin Resistance in Myxoid Liposarcomas

Comparison of in vitro and in vivo biological effects of trabectedin, lurbinectedin (PM01183) and Zalypsis® (PM00104).

Determination of total and lactone form of a new camptothecin derivative gimatecan (ST1481) and its metabolite ST1698 in human plasma by high-performance liquid chromatography with fluorimetric detection.

Differences between in vivo and in vitro sensitivity to imatinib of Bcr/Abl+ cells obtained from leukemic patients.

Establishment and characterisation of a new patient-derived model of myxoid liposarcoma with acquired resistance to trabectedin

Expression of thrombospondin-1 by tumor cells in patient-derived ovarian carcinoma xenografts.

G-quadruplex ligand RHPS4 potentiates the antitumor activity of camptothecins in preclinical models of solid tumors.

HMGA1/E2F1 axis and NFkB pathways regulate LPS progression and trabectedin resistance

HPLC-MS/MS method to measure trabectedin in tumors: preliminary PK study in a mesothelioma xenograft model

Heterogeneity of paclitaxel distribution in different tumor models assessed by MALDI mass spectrometry imaging

High-performance liquid chromatographic assay for the determination of Aloe Emodin in mouse plasma.

High-performance liquid chromatographic assay for the determination of the novel C-Seco-taxane derivative (IDN 5390) in mouse plasma

High-performance liquid chromatographic assay for the determination of the novel taxane derivative IDN5109 in mouse plasma

Human malignant mesothelioma is recapitulated in immunocompetent BALB/c mice injected with murine AB cells.

IDN 5390: an oral taxane candidate for protracted treatment schedules

Inactivation of DNA repair triggers neoantigen generation and impairs tumour growth.

Increased sensitivity to platinum drugs of cancer cells with acquired resistance to trabectedin

Longitudinal tracking of triple labeled umbilical cord derived mesenchymal stromal cells in a mouse model of Amyotrophic Lateral Sclerosis

Lurbinectedin reduces tumour-associated macrophages and the inflammatory tumour microenvironment in preclinical models

Mode of action of trabectedin in myxoid liposarcomas.

Novel models of myxoid liposarcoma xenografts mimicking the biological and pharmacologic features of human tumors.

OTX015 (MK-8628), a novel BET inhibitor, exhibits antitumor activity in non-small cell and small cell lung cancer models harboring different oncogenic mutations

PEGylated Nanoparticles Obtained through Emulsion Polymerization as Paclitaxel Carriers

Past-in-the-Future. Peak detection improves targeted mass spectrometry imaging

Patient-derived solitary fibrous tumour xenografts predict high sensitivity to doxorubicin/dacarbazine combination confirmed in the clinic and highlight the potential effectiveness of trabectedin or eribulin against this tumour.

Pharmacokinetics and antineoplastic activity of galectin-1-targeting OTX008 in combination with sunitinib.

Pharmacokinetics and metabolism in mice of IDN 5390 (13-(N-Boc-3-i-butylisoserinoyl)-C-7,8-seco-10-deacetylbaccatin III), a new oral c-seco-taxane derivative with antiangiogenic property effective on paclitaxel-resistant tumors.

Promising in vivo efficacy of the BET bromodomain inhibitor OTX015/MK-8628 in malignant pleural mesothelioma xenografts

Readily prepared biodegradable nanoparticles to formulate poorly water soluble drugs improving their pharmacological properties: The example of trabectedin

Reduced expression of the ROCK inhibitor Rnd3 is associated with increased invasiveness and metastatic potential in mesenchymal tumor cells

Role of Macrophage Targeting in the Antitumor Activity of Trabectedin

Self-Assembling PCL-Based Nanoparticles as PTX Solubility Enhancer Excipients

Sequence dependent antitumour efficacy of the vascular disrupting agent ZD6126 in combination with paclitaxel.

Snail levels control the migration mechanism of mesenchymal tumor cells.

The bromodomain inhibitor OTX015 (MK-8628) exerts anti-tumor activity in triple-negative breast cancer models as single agent and in combination with everolimus

The effects of vandetanib on paclitaxel tumor distribution and antitumor activity in a xenograft model of human ovarian carcinoma

The impairment of the High Mobility Group A (HMGA) protein function contributes to the anticancer activity of trabectedin

The isothiocyanate produced from glucomoringin inhibits NF-kB and reduces myeloma growth in nude mice in vivo.

The neuroprotective effect of erythropoietin in docetaxel-induced peripheral neuropathy causes no reduction of antitumor activity in 13762 adenocarcinoma-bearing rats

Trabectedin efficacy in Ewing sarcoma is greatly increased by combination with anti-IGF signaling agents.

Tumor-associated macrophages and anti-tumor therapies: complex links

Wee1 inhibitor MK1775 sensitizes KRAS mutated NSCLC cells to sorafenib.